.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Army
Argus Health
Harvard Business School
Queensland Health
Novartis
Medtronic
US Department of Justice
Merck
AstraZeneca
Chinese Patent Office

Generated: September 24, 2017

DrugPatentWatch Database Preview

EMBOLEX Drug Profile

« Back to Dashboard

Which patents cover Embolex, and what generic Embolex alternatives are available?

Embolex is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in EMBOLEX is dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride. There are five drug master file entries for this compound. Additional details are available on the dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride profile page.

Summary for Tradename: EMBOLEX

Patents:0
Applicants:1
NDAs:1
Bulk Api Vendors: see list72
Clinical Trials: see list1
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:EMBOLEX at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis
EMBOLEX
dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride
INJECTABLE;INJECTION018885-001Nov 30, 1984DISCNNoNo► Subscribe► Subscribe► Subscribe
Novartis
EMBOLEX
dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride
INJECTABLE;INJECTION018885-002Nov 30, 1984DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: EMBOLEX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis
EMBOLEX
dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride
INJECTABLE;INJECTION018885-001Nov 30, 1984► Subscribe► Subscribe
Novartis
EMBOLEX
dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride
INJECTABLE;INJECTION018885-002Nov 30, 1984► Subscribe► Subscribe
Novartis
EMBOLEX
dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride
INJECTABLE;INJECTION018885-002Nov 30, 1984► Subscribe► Subscribe
Novartis
EMBOLEX
dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride
INJECTABLE;INJECTION018885-001Nov 30, 1984► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
Novartis
Covington
Mallinckrodt
Boehringer Ingelheim
Moodys
Teva
Cerilliant
Cipla
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot